This $403,423 federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports research to investigate the molecular mechanisms of antibiotic inhibition of ribosomal subunit joining in bacteria. The project aims to characterize the kinetic, thermodynamic, and structural dynamics of the subunit joining process and elucidate how antibiotics impact these parameters. The research comprises three...
The National Institutes of Health's National Institute of General Medical Sciences awarded Oragenics, Inc. a $769,962 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to support computer-aided design of novel lantibiotics with improved antibiotic properties from August 1, 2021 to July 31, 2022. Specifically, the awardee will investigate the molecular interaction between the lantibiotic mutacin 1140 and its target in silico to rank analogs, synthesize and...
This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify mechanisms of resistance to pathogen-specific antibacterial antisense compounds known as peptide-phosphorodiamidate morpholino oligomers (PPMOs) and develop strategies to overcome them. The $254,478 award to the University of Texas Southwestern Medical Center will fund a 2-year project...
This National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase I award to Bactria Pharmaceuticals LLC is providing $274,937 to develop therapeutic drugs that restore antibiotic sensitivity in bacteria that cause severe healthcare-associated infections. The goal is to combat antimicrobial resistance in gram-negative pathogens through the use of small molecule efflux pump inhibitors (EPIs). The project involves three key activities: cryo-electron microscopy to understand...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $802,798 to The Research Foundation For The State University Of New York (RF SUNY) to develop a novel class of antimicrobial agents called "Biamyxins" (BMX) for treating multidrug-resistant Gram-negative bacterial infections. The funding supports further optimization of the lead BMX compound...
The National Institute of General Medical Sciences (NIGMS) awarded a $193,750 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to San Francisco State University (SFSU) to investigate the flavin-dependent thymidylate synthase enzyme as a potential antimicrobial target. The research aims to: 1) study the molecular mechanism of the M. tuberculosis and C. difficile flavin-dependent thymidylate synthase enzymes to understand inhibition, 2) develop biochemical...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,379,734 to the University of Texas at Austin to conduct research on microcin antibacterial proteins. The goal is to better understand how these small proteins can overcome the outer membrane permeability barrier of Gram-negative bacteria, a major challenge in developing new antibiotics. The research aims to link...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $424,076 to the University of Washington for computational design and experimental validation of macrocyclic inhibitors targeting bacterial type I signal peptidase (SPase I). The research aims to develop broad-spectrum antibiotic candidates that can address the growing global threat of antibiotic resistance....
This federal Project Grant award of $299,163 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop a novel antimicrobial approach that combines endolysin proteins with self-replicating mRNA (RepRNA) delivery using lipid nanoparticles. The key objectives of this Phase I proof-of-concept study are to: 1) evaluate whether RepRNA can successfully express a lysin that targets vancomycin-resistant...
This $2,308,174 federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to develop new antibiotic combinations and dosing strategies to combat carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae. The award, which runs from August 8, 2024 to May 31, 2029, involves three projects and three cores conducted by the University of Florida, the...